The little or no inhibition of KIT signaling by imatinib in our GIST-RX1 and GIST-RX2 PDX models is consistent with the findings in GIST-T1/816 and GIST-T1/670 models. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.